68 results
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition) pending … . There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting
8-K
EX-1.1
HEPA
Hepion Pharmaceuticals Inc
21 Jul 23
Entry into a Material Definitive Agreement
4:41pm
, suit, audit, survey, proceeding, hearing, enforcement, investigation, arbitration or other action (“Action”) from any court or arbitrator … , and, to the Company’s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. The Company
S-8
EX-5.1
HEPA
Hepion Pharmaceuticals Inc
14 Jul 23
Registration of securities for employees
5:12pm
is based on matters of fact, we have relied on such certificates and comparable documents without independent investigation. We have made such other
8-K
EX-10.2
538vsn
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-10.1
jemwcb kvt
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-1.1
uuwtk6kq
17 Feb 21
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
8:06am
S-8
EX-5.1
8dboc7a10p1e
19 Jan 21
Registration of securities for employees
12:00am
8-K
EX-1.1
6bvwwwlb9jpem7l
27 Nov 20
Hepion Pharmaceuticals Prices Public Offering
1:48pm
8-K
EX-99.1
lu73fc
12 Aug 20
Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431’s Antiviral Properties
8:46am